*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Prof.Shanta Dhar, University of Georgia
Targeted Nanocarriers for Delivery of Contrast Agents and Therapeutics
Analytical Chemistry Seminar Series
The potential benefits of integrating nanomaterials with properties such as biodegradability, magnetization, fluorescence, and near-infrared absorption into a single object of nanoscale dimensions can lead to the development of hybrid nanocarrier platforms for simultaneous targeting, imaging, and combination therapy administration. We are developing hybrid nanoparticle (NP) systems for their potential use in combination therapy of cancer and image-guided therapy of atherothrombotic vascular diseases.
Mitochondrial dysfunctions cause many human disorders. A platform technology of carrying bioactive molecules to the mitochondrial matrix could be of enormous potential benefit in therapeutics. We are developing a rationally designed, programmable NP platform for the diagnosis and targeted delivery of therapeutics for mitochondrial dysfunction related diseases. An optimized formulation for maximal mitochondrial uptake was identified through in vitro screening of a library of charge and size varied NPs and the uptake was studied by qualitative and quantitative investigations of cytosolic and mitochondrial fractions of cells treated with mitochondria-targeted blended NPs. The versatility of this platform was demonstrated by studying a variety of mitochondria-acting therapeutics for different applications. These include mitochondria targeting chemotherapeutics for cancer, mitochondrial antioxidant for Alzheimer’s disease, and mitochondrial uncoupler for obesity. On the cardiovascular front, we are developing a long-circulating hybrid NP platform to selectively target macrophages and sense apoptosis for detection of plaque vulnerable to embolism.
For more information contact Prof. Andrew Lyon (404-894-4090).
